About TRION Pharma

About company

TRION Pharma GmbH is a privately held biopharmaceutical company that has established a novel approach to cancer immunotherapy. The Company’s unique family of trifunctional therapeutic antibodies, called Triomab®, simultaneously activates multiple immune defense mechanisms against cancer. Removab® (catumaxomab), the most advanced candidate of the Triomab® family, received EU market approval for the intraperitoneal treatment of malignant ascites. Removab® is not only the first drug indicated for the treament of malignant ascites, but also the first approved bispecific, trifunctional antibody worldwide. TRION employs about 90 people in Munich for development and cGMP-manufacturing of its antibody products.